JCAR 015

Drug Profile

JCAR 015

Alternative Names: anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/CD28/zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; CD28-modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; JCAR 15; JCAR015

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute lymphoblastic leukaemia
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 23 Nov 2016 Juno Therapeutics places voluntary clinical hold on the phase II ROCKET trial in Acute lymphoblastic leukaemia due to two cerebral oedema events
  • 22 Nov 2016 Celgene Corporation and Juno Therapeutics plan the phase II ORBIT trial for Acute lymphoblastic leukaemia (Second-line therapy or greater) in Belgium, France, Germany, Italy, Spain, Switzerland and United Kingdom (IV) (NCT02973191)
  • 01 Aug 2016 Juno Therapeutics initiates an observational, long-term follow-up trial for Acute lymphoblastic leukaemia in USA (IV) (NCT02813252)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top